within Pharmacolibrary.Drugs.ATC.L;

model L01XK05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.51,
    Cl             = 26.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.113,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015166666666666667,
    Tlag           = 11.4
  );

  annotation(Documentation(
    info ="<html><body><p>Veliparib (ATC code L01XK05) is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, used primarily in oncology as a targeted therapy for cancers such as ovarian and breast cancer, particularly in patients with BRCA mutations. Veliparib is not broadly approved as a monotherapy but has been investigated in combination with DNA-damaging chemotherapies in clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced solid tumors (mainly ovarian or BRCA-associated breast cancer) after single oral administration, median age 54, mixed sex.</p><h4>References</h4><ol><li><p>Nuthalapati, S, et al., &amp; Xiong, H (2018). Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. <i>Clinical pharmacokinetics</i> 57(1) 51–58. DOI:<a href=&quot;https://doi.org/10.1007/s40262-017-0547-z&quot;>10.1007/s40262-017-0547-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28497258/&quot;>https://pubmed.ncbi.nlm.nih.gov/28497258</a></p></li><li><p>Singh, R, et al., &amp; Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. <i>Cancer chemotherapy and pharmacology</i> 83(2) 319–328. DOI:<a href=&quot;https://doi.org/10.1007/s00280-018-3731-4&quot;>10.1007/s00280-018-3731-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30456480/&quot;>https://pubmed.ncbi.nlm.nih.gov/30456480</a></p></li><li><p>Li, J, et al., &amp; LoRusso, P (2014). Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 20(15) 3931–3944. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-14-0791&quot;>10.1158/1078-0432.CCR-14-0791</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24947923/&quot;>https://pubmed.ncbi.nlm.nih.gov/24947923</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK05;
